Charles Schwab Investment Management Inc Chinook Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$18.66 - $38.58 $53,890 - $111,419	-2,888 Reduced 0.76%	375,239 $14.4 Million
Q1 2023 May 11, 2023	SELL	$21.53 - $26.8 $120,245 - $149,678	-5,585 Reduced 1.46%	378,127 $8.75 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $171,861 - $252,303	9,225 Added 2.46%	383,712 $10.1 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $3.77 Million - $5.03 Million	215,075 Added 134.92%	374,487 $7.36 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $603,526 - $901,215	47,937 Added 43.0%	159,412 $2.79 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $112,675 - $156,452	9,374 Added 9.18%	111,475 $1.82 Million
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $187,085 - $294,541	17,501 Added 20.69%	102,101 $1.67 Million
Q3 2021 Nov 16, 2021	BUY	$11.5 - $14.86 $53,003 - $68,489	4,609 Added 5.76%	84,600 $1.08 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $527,326 - $735,930	38,774 Added 94.07%	79,991 $1.13 Million
Q1 2021 May 17, 2021	BUY	$14.17 - $19.11 $269 - $363	19 Added 0.05%	41,217 $641,000
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $490,256 - $861,450	41,198 New	41,198 $654,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.